What is the appropriate oral (PO) to intravenous (IV) conversion for lacosamide, including dosing, infusion rate, and adjustments for renal impairment?

PO to IV Conversion for Lacosamide

Lacosamide can be directly converted from oral to intravenous administration at the same total daily dose without any adjustment, as the oral bioavailability is approximately 100% and both formulations are bioequivalent. 1

Direct 1:1 Conversion

• Same dose, same frequency: Convert the oral dose to IV at an equivalent milligram-per-milligram basis
• The 30- and 60-minute IV infusions are bioequivalent to oral tablets 1
• No loading dose adjustment needed when switching routes

Infusion Rate Guidelines

Standard infusion duration: 30-60 minutes 1, 2, 3

• 15-minute infusions: Bioequivalent for AUC but produce 20% higher Cmax than oral tablets; still safe and well-tolerated 1, 4
• 10-minute infusions: Evaluated and found safe in clinical trials 2
• Infusions as short as 15 minutes are supported for short-term replacement (2-5 days) 2

Practical Infusion Approach:

• Use 30-60 minute infusions for routine conversions
• 15-minute infusions acceptable when faster administration needed
• No increase in adverse events with shorter infusion durations 2

Renal Impairment Adjustments

Mild to moderate renal impairment (CrCl ≥30 mL/min): No dose adjustment required 1

Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease:

• Reduce maximum daily dose by 25% 1
• Total body clearance decreases by approximately 20% in mild-moderate impairment and significantly more in severe impairment 5

Hemodialysis patients:

• Lacosamide is effectively removed by hemodialysis (approximately 50% cleared during 4-hour session) 1, 5
• Provide supplemental dose of up to 50% of the regular dose after hemodialysis 1

Hepatic Impairment Adjustments

Mild to moderate hepatic impairment (Child-Pugh A-B):

• Reduce maximum daily dose by 25% 1
• Plasma concentrations increase 50-60% in moderate hepatic impairment 1

Severe hepatic impairment: Not recommended (not studied) 1

Loading Dose Considerations

While not specifically a PO-to-IV conversion issue, if rapid therapeutic levels are needed:

• 200 mg IV loading dose approximates steady-state concentrations comparable to 100 mg twice daily oral maintenance 1
• Loading doses of 200-300 mg IV over 15 minutes are well-tolerated 4
• 400 mg loading dose associated with higher frequency of dose-related adverse events (dizziness, nausea, vomiting) 4

Common Adverse Effects During IV Administration

Most treatment-emergent adverse events occur within first 4 hours post-infusion 4:

• Dizziness, somnolence, nausea (dose-related, incidence ≥10%)
• Headache, back pain, injection site pain (less common) 2, 6
• Injection site events are rare and not linked to infusion rate 2

Critical Safety Considerations

• PR interval prolongation: Lacosamide causes dose-related PR interval increases; monitor ECG in patients with cardiac conduction abnormalities 1
• Cardiac effects: No QTc prolongation, but small increases in PR interval (7.3 ms at 400 mg/day, 11.9 ms at 800 mg/day) 1
• Elderly patients require cautious titration due to increased cardiac conduction abnormalities and polypharmacy 1